Attached files
| file | filename |
|---|---|
| 8-K - Vystar Corp | v165544_8k.htm |
Vystar
Investor Presentation NOVEMBER 2009
Why Vytex NRL? Latex Allergy
Concerns 3%* general
population 17% healthcare
workers 10% condom users Global
Environmental Awareness Vytex: all natural,
renewable
resource Increased use
petroleum-based
synthetics Human
carcinogenicity/ toxicity Proven Raw
Material 40,000+ products
made with
natural rubber
latex $2.6B global market Superior
performance
over synthetics *Source: American Latex Allergy Association
1.6% 22.4K Mexico US Europe 4.2% 59K US Europe 6.8% 60K US SE Asia India 12.5% 75K SE Asia India 35.8% 504K SE Asia India US Potential: 1.3 million metric tonnes annually (2010) Source: International Rubber Study Group, 2006 Large Global Marketplace ($2.6B) Gloves Threads Foams Other Dip Carpet Adhesives Balloons Condoms Shoes Catheters Other
Antunes et al. 2002 Mat Chem Phys 76:243-249 3 Crystals Generated in Distilled Water NRL Technology Vytex technology uses aluminum hydroxide to remove proteins Proteins and 3 crystals and impurities
removed during
centrifugation
Protein Al(OH)3 crystal Field latex
containing water
soluble protein Solid Al(OH)3 Protein-adsorbed Al(OH)3 Protein-adsorbed Al(OH)3 Recovery & Recycling Skim layer Centrifugation
Vytex: An Adaptive Technology Latex production Malaysia/Thailand India Guatemala
The Accomplishments and Future of Vystar - R & D Technical Regulatory Line Extensions Process Improvements to Reduce COGS Advanced Material Testing to Enhance Value Clinical Studies: Peer Reviewed and Published - - Industry Leadership ASTM Category 5 Global Participation in Key Industry Conferences SEC
Reporting Company (August 2009) (October 2009) (October 2009) (Low Nitrosamine, PV Condom) Reduce COGS Advanced Material Testing Clinical Studies: Peer Reviewed and Published US FDA Expansion of Protein Claims 510(k) Condoms and Exam Gloves Lowest Protein Claim for Condoms on Market
Management Team Extensive sales, marketing
and advertising
management experience
B2B and B2C Successful IPO and
secondary offering
experience Broad regulatory and
financial expertise President/CEO Executive Vice President, Business
Development and Marketing , Vice President, Technical Sales , Acting Chief Financial Officer , General Counsel and Chief Legal Officer Organizational Depth
Board of Directors Broad experience in capital
markets Extensive experience in
OTC trading Community bank start-up
expertise Entrepreneurial success Proven leadership across
diverse markets and
industries William R. Doyle, President/CEO, Chairman of the Board Directors CEO, Medicraft, Inc. Founder/Owner, Diamond II Investments, Oncology Molecular Imaging, Pediatric Urgent Care Vice President, Investments,
MidSouth Capital Senior Vice President, Commerce Street Capital Steptoe & Johnson (Advisor to Board)
Technical Catharine C. Calkins-Burke, Ph.D Ranjit K. Matthan, Ph.D, KA Prevulcanised P Ltd. Quan-Tec Air, Inc.; formerly Mayo Foundation Jasmine Elastomerics Selvaraj V M Muthuraja, Stratoshift Technologies, Sdn Bhd Clinical formerly Shands at University of Florida , UCLA Medical Center formerly Ohio State University Medical Center Parker Lee, formerly CEO, Ansell Medical Products, Ansell Ltd. Advisors Extensive raw materials research and development Known expertise on natural rubber latex Active management P&L responsibilities and purchasing influence Noted clinical authors and speakers
Market Pricing Trends
Financial Projections THE FOLLOWING PROJECTIONS ARE FORWARD-LOOKING STATEMENTS. WE MAY NOT ACTUALLY ACHIEVE THE PROJECTIONS DISCLOSED AND YOU SHOULD NOT PLACE UNDUE RELIANCE UPON SUCH FORWARD-LOOKING STATEMENTS. ACTUAL RESULTS COULD DIFFER MATERIALLY FROM SUCH PROJECTIONS. IN OUR PRIVATE PLACEMENT MEMORANDUM DATED OCTOBER 28, 2009, WE HAVE INCLUDED IMPORTANT FACTORS IN THE “RISK FACTORS” SECTION OF THE MEMORANDUM THAT WE BELIEVE COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THE PROJECTIONS THAT WE MAKE. OUR FORWARD-LOOKING STATEMENTS DO NOT REFLECT THE POTENTIAL IMPACT OF ANY FUTURE ACQUISITIONS, MERGERS, DISPOSITIONS, JOINT VENTURES OR INVESTMENTS WE MAY MAKE. YOU SHOULD READ OUR PRIVATE PLACEMENT MEMORANDUM COMPLETELY AND WITH THE UNDERSTANDING THAT OUR ACTUAL FUTURE RESULTS MAY BE MATERIALLY DIFFERENT FROM WHAT WE EXPECT. WE DO NOT ASSUME ANY OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS, WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE, EXCEPT AS REQUIRED BY LAW.
2009 Projections Vystar Corporation FY 2009 Actual Results Projected Q1 Q2 Q3 Q4 Total Net Product Sales $ 11 $ 1 $ 6 $ 32 $ 50 Licensing Revenue - - - - - Total Net Revenue 11 1 6 32 50 Gross Margin - Product 3 (1) - 6 8 Gross Margin - Licensing - - - - - Operating expenses 511 560 485 474 2,030 Net Income (Loss) $ (508) $ (561) $ (485) $ (468) $ (2,022) Cash Balance, End of Period $ 1,253 $ 1,345 $ 722 $ 409 $ 409 Sales, in tonnes: 3.5 0.5 2.7 16.0 22.7 Product Sales 3.5 0.5 2.7 16.0 22.7 Licensing Sales - - - - -
2010 Projections Vystar Corporation FY 2010 Projected Results Q1 Q2 Q3 Q4 Total Net Product Sales $ 74 $ 123 $ 233 $ 225 $ 655 Licensing Revenue 17 87 413 499 1,016 Total Net Revenue 91 210 646 724 1,671 Gross Margin - Product 20 33 59 56 168 Gross Margin - Licensing 17 87 413 499 1,016 Operating expenses 564 558 524 501 2,147 Net Income (Loss) $ (527) $ (438) $ (52) $ 54 $ (963) Cash Balance, End of Period $ 156 $ 12 $ 2 $ 303 $ 303 Sales, in tonnes: 53.0 151.0 546.0 632.0 1,382.0 Product Sales 35.0 59.0 111.0 107.0 312.0 Licensing Sales 18.0 92.0 435.0 525.0 1,070.0
2011 Projections Vystar Corporation FY 2011 Projected Results Q1 Q2 Q3 Q4 Total Net Product Sales $ - $ - $ - $ - $ - Licensing Revenue 954 1,178 1,637 1,876 5,645 Total Net Revenue 954 1,178 1,637 1,876 5,645 Gross Margin - Product - - - - - Gross Margin - Licensing 944 1,166 1,620 1,858 5,588 Operating expenses 705 651 621 632 2,609 Net Income (Loss) $ 239 $ 515 $ 999 $ 1,226 $ 2,979 Cash Balance, End of Period $ 512 $ 1,086 $ 1,965 $ 3,197 $ 3,197 Sales, in tonnes: 1,004.0 1,240.0 1,723.0 1,975.0 5,942.0 Product Sales - - - - - Licensing Sales 1,004.0 1,240.0 1,723.0 1,975.0 5,942.0
Vystar Offering (Refer to PPM) Offer Up to 1,000,000 Shares of
Common Stock and Warrants to
Purchase up to
1,000,000 Shares of
Common Stock Offering Offer Total Shares
Outstanding Offer Price Offering Price $2.00 per Share $2,000,000 Warrants 500,000 at $1.50/share Exercisable within 12
months 500,000 at $3.25/share Exercisable within 24 months 12,787,274
Why Invest in Vystar? Large Global Market 40,000 products
made with
natural rubber
latex $2.6B market Fully Commercialized Address Allergenicity
Concerns Virtually
undetectable
levels of
antigenic protein Endorsed by
American Latex
Allergy Association Green
Footprint All natural, renewable
resource Biodegradable No VOCs No known human
carcinogens FDA 510(k)
Clearances Highly prized
510(k) clearance
for lowest
antigenic protein
claim on market